$0.2196
Revenue is down for the last 4 quarters, 2.06M → -3.55M (in $), with an average decrease of 166.6% per quarter
Netprofit is down for the last 4 quarters, -8.3M → -44.97M (in $), with an average decrease of 131.5% per quarter
In the last 1 year, Idexx Laboratories, Inc. has given 21.6% return, outperforming this stock by 99.9%
In the last 3 years, Idexx Laboratories, Inc. has given 48.5% return, outperforming this stock by 139.9%
4.55%
Downside
Day's Volatility :7.16%
Upside
2.74%
9.09%
Downside
52 Weeks Volatility :85.19%
Upside
83.7%
Period | ONCOCYTE CORP | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -37.1% | 0.7% | -7.0% |
6 Months | -54.35% | -7.9% | -6.5% |
1 Year | -78.31% | -2.0% | -6.8% |
3 Years | -91.41% | 25.4% | 24.7% |
Market Capitalization | 36.2M |
Book Value | $0.32 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.09 |
PEG Ratio | 0.0 |
Wall Street Target Price | 0.35 |
Profit Margin | 0.0% |
Operating Margin TTM | -3129.37% |
Return On Assets TTM | -14.94% |
Return On Equity TTM | -18.4% |
Revenue TTM | 875.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -21.8% |
Gross Profit TTM | 188.0K |
EBITDA | -22.9M |
Diluted Eps TTM | -0.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.13 |
EPS Estimate Next Year | -0.2 |
EPS Estimate Current Quarter | -0.08 |
EPS Estimate Next Quarter | -0.05 |
What analysts predicted
Upside of 59.38%
Sell
Neutral
Buy
ONCOCYTE CORP is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() ONCOCYTE CORP | -15.01% | -54.35% | -78.31% | -91.41% | -91.41% |
![]() IDEXX Laboratories, Inc. | 0.53% | 7.93% | 21.61% | 48.46% | 114.73% |
![]() Agilent Technologies Inc. | -13.57% | -25.32% | -9.95% | 28.76% | 83.43% |
![]() Thermo Fisher Scientific, Inc. | -4.49% | -7.75% | -8.9% | 48.36% | 142.51% |
![]() Danaher Corp. | -4.16% | -15.15% | -14.85% | 39.37% | 128.42% |
![]() IQVIA Holdings Inc. | 7.2% | -8.62% | -9.58% | 31.31% | 96.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() ONCOCYTE CORP | NA | NA | 0.0 | -0.13 | -0.18 | -0.15 | 0.0 | 0.32 |
![]() IDEXX Laboratories, Inc. | 56.2 | 56.2 | 7.21 | 9.69 | 0.94 | 0.22 | 0.0 | 10.13 |
![]() Agilent Technologies Inc. | 26.91 | 26.91 | 2.36 | 5.63 | 0.25 | 0.1 | 0.01 | 18.96 |
![]() Thermo Fisher Scientific, Inc. | 33.19 | 33.19 | 4.28 | 23.68 | 0.14 | 0.05 | 0.0 | 109.55 |
![]() Danaher Corp. | 24.72 | 24.72 | 3.24 | 9.38 | 0.14 | 0.06 | 0.0 | 68.31 |
![]() IQVIA Holdings Inc. | 35.16 | 35.16 | 1.48 | 10.42 | 0.18 | 0.05 | 0.0 | 31.98 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() ONCOCYTE CORP | Buy | $36.2M | -91.41% | NA | 0.0% |
![]() IDEXX Laboratories, Inc. | Buy | $38.6B | 114.73% | 56.2 | 20.38% |
![]() Agilent Technologies Inc. | Buy | $35.3B | 83.43% | 26.91 | 19.09% |
![]() Thermo Fisher Scientific, Inc. | Buy | $196.1B | 142.51% | 33.19 | 13.75% |
![]() Danaher Corp. | Buy | $169.4B | 128.42% | 24.72 | 22.4% |
![]() IQVIA Holdings Inc. | Buy | $36.5B | 96.53% | 35.16 | 7.28% |
BROADWOOD CAPITAL Inc
PURA VIDA INVESTMENTS, LLC
Awm Investment Company Inc
Vanguard Group Inc
Defender Capital, LLC.
BlackRock Inc
ONCOCYTE CORP’s price-to-earnings ratio stands at None
Read MoreOncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
Organization | ONCOCYTE CORP |
Employees | 75 |
CEO | Dr. Douglas T. Ross M.D., Ph.D. |
Industry | Health Technology |
PowerShares SP MidCap Low Volatility ETF
$51.27
+2.97%
SPDR NYSE Technology ETF
$132.98
+0.91%
ProShares UltraPro Dow30 ETF
$57.18
+6.4%
Teucrim Soybean Fund
$24.73
+1.24%
CRESCENT CAPITAL BDC INC
$13.65
+0.15%
Fusion Pharmaceuticals Inc
$4.90
-2.39%
AMC Networks Inc.
$11.64
+2.02%
EVGO INC CL A
$4.03
+0.5%
CONNECT BIOPHARMA HOLDINGS L
$1.22
+9.91%